Horizon Discovery Group

Horizon Discovery is a revenue-generating life science group supplying research tools to organizations engaged in translational genomics research and the development of personalized medicines. Horizon has a diverse and international customer base of over 1,200 organizations across more than 50 countries, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centers. The Group supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.
Company Type
Company Sub-Type
Twitter Account
@HorizonGenomics

Illingworth Group Ltd

Illingworth Research is a full service clinical CRO with experience across all phases of development from Phase I / proof of concept studies to post-marketing studies for small molecules, biotechnology products, medical devices and diagnostics. With a network of clinical infrastructure covering most therapeutic areas varying from clinical research units, primary, secondary and tertiary care sites across Europe and with partners in North America and Australasia, Illingworth has the capability to deliver large multi-centre global studies on time and within budget. Illingworth also provides research nurses for patient homecare to support studies for optimisation of patient retention and compliance. Illingworth also offers a medical photography service.

Company Type
Company Sub-Type
Twitter Account
@illingworthrsch

Image Analysis

IA-Group is a strategic partner to bio-pharmacutical companies. We bring extensive therapeutic knowledge and regulatory expertise in strategic use of clinical imaging to enhance understanding of the mode of action, to increase the efficiency of clinical decisions and to accelerate drug development.

IA’s operations team leverage our global footprint and the next-generation cloud based proprietry platform Dynamika to de-risk trial execution and to ensure data quality and integrity. Our venture arm pioneer unique targeted investment and risk-sharing models to enable our clients to reach the next value inflection point faster. We fuse decades of theraputic insight and agile culture to meet today's speed and high standard of therapeutic innovation.

Company Type
Company Sub-Type
Twitter Account
@ImageAnalysisUK
News Page URL
@ImageAnalysisUK

Imanova

Imanova has world-leading expertise in imaging sciences and their application to the understanding of disease and translational drug development. An innovative joint venture, Imanova’s shareholders are the UK's Medical Research Council and three world-class London universities: Imperial College London, King’s College London and University College London.

Imanova is a company with a depth of understanding in drug development and extensive experience using imaging to facilitate the development pipeline. Our academic expertise and extensive links with clinicians and scientists in our shareholder institutions provide unrivalled capabilities to facilitate drug development.

Company Type
Twitter Account
@ImanovaImaging

PCI Pharma Services

PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market. With facilities in North America and Europe, PCI supports pharmaceutical and biotech companies with products destined for more than 100 countries around the world. PCI provides services for each stage of the product lifecycle - from early Phase I through commercial launch and long-term supply - and partners with customers to provide key insight and expertise in enabling successful commercialization and bringing lifesaving medications to patients.

Precision Oncology

    Precision Oncology is proud to offer the first comprehensive, fully integrated oncology clinical development solution. We are devoted exclusively to oncology, and passionate about improving the lives of cancer patients. By combining the progressive science of biomarkers and analytics with our excellence in oncology clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Company Type
Company Sub-Type
Twitter Account
@PrecisionOnc

Selcia Ltd

Contract Research Services in Integrated Drug Discovery and Custom Radiolabelling. A leading worldwide provider of integrated drug discovery, medicinal chemistry and GMP certified 14C custom radiolabelling services, Selcia is a self-funded, profitable, private company with around 80 employees operating from state-of-the-art laboratories. SELCIA DISCOVERY offers integrated drug discovery services including screening biology, medicinal chemistry, ADME/PK and in vivo PK work.
Company Type
Company Sub-Type
Keywords
Twitter Account
@SelciaLtd

Sygnature Discovery Ltd

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise.  Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies.  Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography.  Sygnature has an enviable track record of success in delivering multiple clinical candidates.

Company Type
Company Sub-Type
Twitter Account
@SygnatureDiscov

Syne qua non Ltd

Syne qua non, established in 1996, is one of the largest functional biometrics suppliers in Europe providing global pharma, biotech, medical device and animal health partners with innovative, cost effective development services specializing in: • clinical data management through optimal process design with paper or EDC data capture solutions • statistical expertise through consultative study design to reporting • effective project management • quality management and consultancy Built on a foundation of CDISC standardization, our flexible and site-friendly EDC tool can be rapidly developed, validated and deployed – built to meet the unique requirements of the study and, coupled with our approach to standardization across all services, will deliver high quality data and in-stream reporting within a competitive pricing model.
Company Type
Company Sub-Type
Twitter Account
@Synequanon

SYNthesis Med Chem

SYNthesis med chem, founded in 2007, is a relatively new player in the chemistry CRO market. We are Australian owned with laboratory facilities in Shanghai China and offices in Australia, the US and the UK. The management team at SYNthesis are experienced drug discovery professionals with expertise across a range of targets (particularly Kinases, GPCRs and epigenetic targets).

Our clients are drawn from biotech, big pharma and academia, we have an outstanding client return rate with several clients working with us across two or more target classes.